866-997-4948(US-Canada Toll Free)

Atopic Dermatitis (AD)-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 144 Pages

DelveInsights Atopic Dermatitis-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of epidemiology and market trend of Atopic Dermatitis for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Atopic Dermatitis from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Atopic Dermatitis till 2025. The Report also covers market drivers, market barriers and unmet medical need.

Our report provides the subtype specific prevalent population i.e., Mild Atopic Dermatitis, Moderate Atopic Dermatitis and Severe Atopic Dermatitis. According to DelveInsight, the prevalent population of Atopic Dermatitis is expected to reach up to XXX cases by the end of 2025 at a CAGR of XX% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

Market is driven by various approved drugs for Atopic Dermatitis such as Elidel (Novartis), Protopic (Fujisawa Healthcare) and Desonate (Bayer Healthcare). There has been a positive impact on the market with the approval of Eucrisa (Pfizer) and Dupilumab (Regeneron Pharmaceuticals/Sanofi) in 2016 and 2017 respectively.
United States contributes the major share of Atopic Dermatitis market as compared to EU5 countries and Japan. The therapeutic market of Atopic Dermatitis in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the Atopic Dermatitis market.
The Report provides detailed historical and forecasted epidemiological data of Atopic Dermatitis in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the Atopic Dermatitis market and insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report covers the detailed historical and forecasted Atopic Dermatitis market covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

1. Report Introduction
2. Atopic Dermatitis Market Overview at a Glance
2.1. Market Share Distribution of Atopic Dermatitis in 2016
2.2. Market Share Distribution of Atopic Dermatitis in 2025
3. Disease Background and Overview
3.1. Etiology
3.2. Risk Factors
3.3. Pathophysiology
3.3.1. Mediators involved in Pathophysiology
3.3.2. Major Mediators for inducing atopic Dermatitis
3.3.3. Emphasis on development of Phosphodiesterase-4 inhibitors
3.3.4. Other Mediators
3.3.5. Potential targets for antipruritic therapy in AD
3.3.6. Triggering factors involved in pathophysiology
3.4. Diagnosis
3.5. American Academy of Dermatology Diagnostic Criteria
3.6. United Kingdom Working Party Diagnostic criteria
3.7. Japanese Dermatological Association Diagnostic Criteria
4. Epidemiology and Patient Population
4.1. Disease Definition
4.2. Population and Forecast Parameters
4.3. Population Methods
4.3.1. Total prevalent cases in US
4.3.2. EU5
4.3.3. Japan
4.4. Prevalent Population of Atopic Dermatitis in 7MM
4.5. Prevalent Population of Atopic Dermatitis by Severity in 7MM
4.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
4.6.1. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in the United States
4.6.2. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Germany
4.6.3. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in France
4.6.4. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Italy
4.6.5. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Spain
4.6.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in United Kingdom
4.6.7. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Japan
4.7. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM
4.8. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
4.9. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM
5. Treatment Practices
6. Treatment Algorithm
6.1. Treatment Goals
6.2. First Line of Treatment
6.3. Second Line of Treatment
7. Treatment Failure
8. Treatment by class
8.1. Topical Therapies
8.2. Systemic therapies
8.3. Approved Drugs for Atopic Dermatitis
9. Emerging Therapies
10. Nemolizumab: Galderma Pharma
10.1. Product Description
10.2. Research and Development
10.3. Product Development Activities
11. Tralokinumab: LEO Pharma
11.1. Product Description
11.2. Research and Development
11.3. Product Development Activities
12. Tradipitant: Vanda Pharmaceuticals
12.1. Product Description
12.2. Research and Development
12.3. Product Development Activities
13. ZPL-389: Novartis
13.1. Product Description
13.2. Research and Development
13.3. Product Development Activities
14. NST-141: Nippon Shinyaku
14.1. Product Description
14.2. Research and Development
14.3. Product Development Activities
15. Serlopitant: Menlo Therapeutics
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities
16. DS107: DS Biopharma
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities
17. Asimadoline: Tioga Pharmaceuticals
17.1. Product Description
17.2. Research and Development
17.3. Product Development Activities
18. GSK2894512: GlaxoSmithKline
18.1. Product Description
18.2. Research Development Activities
18.3. Product Development Activities
19. Lebrikizumab: Roche
19.1. Product Description
19.2. Research and Development
20. DMT210: Dermata Therapeutics
20.1. Product Description
20.2. Research and Development
20.3. Product Development Activities
21. SNA-120: Sienna Biopharmaceutical
21.1. Product Description
21.2. Research and Development
21.3. Product Development Activities
22. RVT-501: Roivant Sciences
22.1. Product Description
22.2. Research and Development
22.3. Product Development Activities
23. OPA-15406: Otsuka Pharmaceutical
23.1. Product Description
23.2. Research and Development
23.3. Product Development Activities
24. Current Unmet Need
25. Atopic Dermatitis: Market Analysis
25.1. Market Outlook
25.2. Market size of Atopic Dermatitis in 7MM
25.3. Market analysis of Atopic Dermatitis in 7MM
26. Atopic Dermatitis: United States Market Outlook
26.1. Market size
27. Atopic Dermatitis: EU5
28. Market Outlook
28.1. Germany Market size
28.2. France Market size
28.3. Italy Market size
28.4. Spain Market size
28.5. United Kingdom Market size
29. Atopic Dermatitis: Japan Market Outlook
29.1. Japan Market size
30. Market Drivers
31. Market Barriers
32. Expert Opinions
32.1. Views on Current treatment options
32.2. Views on emerging therapies
33. Appendix
33.1. Report Methodology
33.2. Consulting Services
33.3. Disclaimer
33.4. About DelveInsight



List of Table

Table 1:Mediators of itch in atopic dermatitis by their role in provocation of itch
Table 2: Targets focused by companies
Table 3: Concept of Atopic Dermatitis by Wise and Sulzberger
Table 4: Hanifin and Rajka Diagnostic Criteria
Table 5: American Academy of Dermatology Diagnostic Criteria
Table 6: United Kingdom Working Party diagnostic criteria
Table 7: Japanese Dermatological Association Diagnostic Criteria
Table 8: Total Prevalent Population of Atopic Dermatitis in 7 MM (2015-2025)
Table 9: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2015-2025)
Table 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in United States (2015-2025)
Table 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2015-2025)
Table 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2015-2025)
Table 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2015-2025)
Table 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2015-2025)
Table 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in UK (2015-2025)
Table 16: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2015-2025)
Table 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2015-2025)
Table 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2015-2025)
Table 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2015-2025)
Table 20: Reasons for noncompliance with medication
Table 21: Topical corticosteroids
Table 22: Topical Calcineurin Inhibitors (TCIs)
Table 23: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
Table 24: Oral Corticosteroids
Table 25: Biologic medications
Table 26: Systemic Immunomodulating agents
Table 27: Emerging therapies
Table 28: 7 Major Market Size of Atopic Dermatitis in USD Million (2015-2025)
Table 29: 7 Major Market Analysis of Atopic Dermatitis in USD Million (2015-2025)
Table 30: Market Size of Atopic Dermatitis in United States, USD Millions (2015-2025)
Table 31: Market Size of Atopic Dermatitis in Germany , USD Million (2015-2025)
Table 32: Market Size of Atopic Dermatitis in France, USD Million (2015-2025)
Table 33: Market Size of Atopic Dermatitis in Italy, USD Million (2015-2025)
Table 34: Market Size of Atopic Dermatitis in Spain , USD Million (2015-2025)
Table 35: Market Size of Atopic Dermatitis in United Kingdom, USD Million (2015-2025)
Table 36:Market Size of Atopic Dermatitis in Japan , USD Million (2015-2025)

List of Chart

Figure 1: Risk Factors for Atopic Dermatitis
Figure 2: Pathophysiology of Atopic Dermatitis
Figure 3: Mediators involved in Pathophysiology of Atopic Dermatitis
Figure 4: Mediators with their mechanism of action in inducing Atopic Dermatitis
Figure 5: Triggering factors involved in pathophysiology of Atopic Dermatitis
Figure 6: Total Prevalent Population of Atopic Dermatitis in 7 MM (2015-2025)
Figure 7: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2015-2025)
Figure 8: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2015-2025)
Figure 9: Prevalent Population of Atopic Dermatitis by Pruritus Burden in United States (2015-2025)
Figure 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2015-2025)
Figure 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2015-2025)
Figure 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2015-2025)
Figure 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2015-2025)
Figure 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in UK (2015-2025)
Figure 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2015-2025)
Figure 16: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2015-2025)
Figure 17: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2015-2025)
Figure 18:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2015-2025)
Figure 19: General Treatment for Atopic Dermatitis
Figure 20: First Line of treatment for Atopic Dermatitis
Figure 21: Second Line of treatment for Atopic Dermatitis
Figure 22: Current Unmet Need for Atopic Dermatitis
Figure 23: 7 Major Market Size of Atopic Dermatitis in USD Million (2015-2025)
Figure 24: 7 Major Market Analysis of Atopic Dermatitis in USD Million (2015-2025)
Figure 25: Market Size of Atopic Dermatitis in United States, USD Millions (2015-2025)
Figure 26: Market Size of Atopic Dermatitis in Germany , USD Million (2015-2025)
Figure 27: Market Size of Atopic Dermatitis in France, USD Million (2015-2025)
Figure 28: Market Size of Atopic Dermatitis in Italy, USD Million (2015-2025)
Figure 29: Market Size of Atopic Dermatitis in Spain, USD Million (2015-2025)
Figure 30: Market Size of Atopic Dermatitis in United Kingdom , USD Million (2015-2025)
Figure 31:Market Size of Atopic Dermatitis in Japan , USD Million (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *